Download Files:
Products Details
Product Description
– Palazestrant is an antiestrogen and antineoplastic agent. Palazestrant in combination with a HER2 inhibitor, works on ER+/HER2+ cancer[1][2].
Web ID
– HY-148789
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C28H36FN3O
References
– [1]WHO Drug Information-World Health Organization (WHO).|[2]Harmon CL, et al. Methods of treating estrogen receptor-associated diseases such as ER+/HER2+ cancer using an estrogen receptor antagonist: World Intellectual Property Organization, WO2023283329. 2023-01-12.
CAS Number
– 2092925-89-6
Molecular Weight
– 449.60
SMILES
– CC(C)(F)CN1[C@H](C2=CC=C(C=C2)OC3CN(C3)CCC)C4=C(C[C@H]1C)C5=CC=CC=C5N4
Clinical Information
– No Development Reported
Research Area
– Cancer; Inflammation/Immunology
Solubility
– 10 mM in DMSO
Target
– Estrogen Receptor/ERR
Pathway
– Vitamin D Related/Nuclear Receptor
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
